Avandia Side Effects
Generic Name: rosiglitazone
Note: This page contains information about the side effects of rosiglitazone. Some of the dosage forms included on this document may not apply to the brand name Avandia.
Not all side effects for Avandia may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to rosiglitazone: oral tablet
In addition to its needed effects, some unwanted effects may be caused by rosiglitazone (the active ingredient contained in Avandia). In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking rosiglitazone:Less common
- Abdominal or stomach pain
- blurred vision
- chest pain or discomfort
- decrease in the amount of urine
- dry mouth
- flushed, dry skin
- fruit-like breath odor
- increased hunger
- increased thirst
- increased urination
- irregular heartbeat
- noisy, rattling breathing
- pain in the shoulders, arms, jaw, or neck
- pale skin
- rapid or unusual weight gain
- swelling of the fingers, hands, feet, or lower legs
- trouble breathing
- unexplained weight loss
- unusual bleeding or bruising
- unusual tiredness or weakness
- cold sweats
- dark urine
- fast heartbeat
- loss of appetite
- slurred speech
- Blue lips and fingernails
- changes in vision
- coughing that sometimes produces a pink frothy sputum
- hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- itching or skin rash
- light-colored stools
- redness of the skin
- yellow eyes or skin
Some of the side effects that can occur with rosiglitazone may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Ear congestion
- general feeling of discomfort or illness
- hoarseness or other voice changes
- joint pain
- muscle aches and pains
- runny or stuffy nose
- sore throat
- trouble sleeping
- Back pain
- pain or tenderness around the eyes and cheekbones
For Healthcare Professionals
Applies to rosiglitazone: oral tablet
The most commonly reported adverse reports included upper respiratory tract infections, injury, and headache.
Major Adverse Cardiovascular Events:
Overall data from long-term rosiglitazone (the active ingredient contained in Avandia) trials including the RECORD, ADOPT, and DREAM trials (rosiglitazone n=6311; control n=7756) showed no difference in overall mortality or major adverse cardiovascular events; however, a meta-analysis of shorter-term trials suggests and increased risk for myocardial infarction with rosiglitazone compared with placebo.
The RECORD trial (Rosiglitazone evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) revealed no significant difference in cardiovascular hospitalization or cardiovascular death (primary outcome) among patients with type 2 diabetes receiving rosiglitazone add-on therapy (n=2220) compared with active control (n=2227); however, there was a significant difference in the incidence of CHF (secondary endpoint). Patients randomized were those who had failed metformin or sulfonylurea monotherapy; mean age: 58 years; 52% male. Following randomization to add-on rosiglitazone or active control (add-on metformin for those inadequately controlled on sulfonylurea or add-on sulfonylurea for those inadequately controlled on metformin) patients were treated to a target glycosylated hemoglobin (HbA1c) of 7% or less. Heart failure was reported in 61 patients receiving add-on rosiglitazone and 29 patients receiving active control.
In a retrospective analysis of 42 clinical trials (mean duration 6 months), rosiglitazone was associated with an increased risk of myocardial ischemia compared with combined active or placebo control (2% versus 1.53%). These events included angina pectoris, angina dyspnea, myocardial infarction, coronary thrombosis, myocardial ischemia, coronary artery disease, and coronary artery disorder. There was an increased risk with combination insulin therapy and in patients receiving nitrates for known coronary heart disease.
Cardiovascular Events in Patients with NYHA Class I and II Heart Failure:
An increased risk of cardiovascular events was observed in a 52-week trial in patients with NYHA Class I and II Heart Failure who were receiving rosiglitazone (n=110) compared with placebo (n=114). These events included: cardiovascular deaths (5% vs 4%), worsening CHF (6% vs 4%), new or worsening edema (25% vs 9%), new or worsening dyspnea (26% vs 17%), increases in CHF medication (33% vs 18%), and cardiovascular hospitalization (19% vs 13%).
-Dose-related edema was reported in rosiglitazone clinical trials. In patients receiving rosiglitazone 8 mg in combination with a sulfonylurea, the incidence of edema was 12.4%. In rosiglitazone monotherapy trials, edema was reported in 4.8% of patients (dose not specified). Healthy volunteers receiving rosiglitazone 8 mg once daily for 8 weeks experienced a statistically significant increase in median plasma volume compared with placebo.
Concomitant Administration with Insulin:
-Edema was reported with higher frequency in the rosiglitazone plus insulin combination trials (insulin, 5.4%; and rosiglitazone with insulin 14.7%). Reports of new onset or exacerbation of CHF occurred at a rate of 1% for insulin alone, 2% (4 mg) and 3% (8 mg) for insulin in combination with rosiglitazone. The coadministration of rosiglitazone and insulin is not recommended.
Common (1% to 10%): Edema, hypertension,
Frequency not reported: Cardiovascular deaths, congestive heart failure (CHF), myocardial infarction, angina, angina pectoris, angina dyspnea, myocardial infarction, coronary thrombosis, myocardial ischemia, coronary artery disease, coronary artery disorder
Anemia was reported in 1.9% of patients receiving rosiglitazone (the active ingredient contained in Avandia) as monotherapy. In combination therapy with metformin, a sulfonylurea, or metformin plus a sulfonylurea, the incidence of anemia was 7.1%, 2.3%, and 6.7%, respectively. Laboratory findings have shown dose-related decreases in hemoglobin and hematocrit; mean decreases in hemoglobin were 1 g/dL and up to 3.3% in hematocrit. These changes primarily occurred during the first 3 months or following a dose increase. They may be related to increased plasma volume.
Common (1% to 10%): Anemia
Frequency not reported: Decrease in WBC counts
Uncommon (0.1% to 1%): Hyperbilirubinemia, ALT elevations
Postmarketing reports: Hepatitis, hepatic enzyme elevations greater than 3 times the upper limit of normal, hepatic failure
Common (1% to 10%): Hyperglycemia, hypoglycemia, hypocholesterolemia
Uncommon (0.1% to 1%): Weight gain
Frequency not reported: Increases in waist and hip circumference
The mechanism of weight gain is unclear, although it probably is due to a combination of fluid retention and fat accumulation. In the ADOPT monotherapy trial, median weight change at 4 years was plus 3.5 kg.
Frequency not reported: Resumption of ovulation in premenopausal, anovulatory women, hormonal imbalance
Postmarketing reports: Anaphylactic reaction, urticaria, angioedema
Postmarketing reports: Rash, pruritus, urticaria, angioedema, Stevens-Johnson syndrome
Postmarketing reports: Diabetic macular edema with decreased visual acuity
Common (1% to 10%): Upper respiratory tract infection, sinusitis
Frequency not reported: Dyspnea
Postmarketing reports: Pulmonary edema, pleural effusions
Common (1% to 10%): Back pain
Frequency not reported: Fractures
Long-term clinical trials have shown an increased incidence of bone fracture in patients receiving drug compared with glyburide or metformin. This increased incidence appeared after the first year and persisted during the trials. The majority of fractures were observed in women and occurred in the upper arm, hand, and foot.
Common (1% to 10%): Diarrhea
Common (1% to 10%): Injury, fatigue
More about Avandia (rosiglitazone)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.